Specific to innovation, we are encouraged by the several new products we introduced this year. As global Orthopedics, Biologics and Bone Growth Therapies continue their strong performance despite lingering macro headwinds. Our strategic investments in our commercial channel and innovation pipeline are paying off. As announced in October, total revenue for the quarter was $114 million, increasing 1% over 2021 on a reported basis and 5% on on a constant currency basis. Starting with our third quarter performance. I will close the call with our perspectives on the balance of 2022 and near-term growth drivers before I open the line for questions. On today's call, I will provide an update of our third quarter performance, review progress against our strategic initiatives and discuss the planned merger with SeaSpine before handing the call over to Doug, who will provide our financial update. Welcome, everyone, and thank you for joining our third quarter 2022 results conference call. At this point, I will turn the call over to Jon. Please refer to today's press release announcing our third quarter 2022 results for reconciliations of these non-GAAP financial measures to our U.S. We believe that in order to properly understand our short-term and long-term financial trends, investors may wish to review these matters as a supplement to the financial measures determined in accordance with U.S. In addition, on today's call, we will refer to various non-GAAP financial measures. If you need copies of these documents, please contact my office at Orthofix in Lewisville, Texas. Some factors that could cause actual results to be materially different from the forward-looking statements made by us on the call include the risk factors disclosed under the heading Risk Factors in our Form 10-K for the year ended Decemand Form 10-Q for the quarter ended September 30, 2022, filed this morning, November 3, 2022, as well as additional SEC filings we make in the future. We do not take any obligation to revise or update such forward-looking statements. The forward-looking statements we will make on today's call are based on our beliefs and expectations as of today, November 3, 2022. Investors are cautioned not to place undue reliance on such forward-looking statements as there is no assurance that the matter contained in such statements will occur. All statements other than those of historical facts are forward-looking statements, including any earnings guidance we provide and any statements about our plans, beliefs, strategies, expectations, goals or objectives. During this call, we will be making forward-looking statements that involve risks and uncertainties. I'll start with the safe harbor statement and then pass it over to Jon. Joining me on the call today are our President and Chief Executive Officer, Jon Serbousek and Chief Financial Officer, Doug Rice. Welcome to the Orthofix Third Quarter 2022 Earnings Call. Thank you, operator, and good morning, everyone. Alex Huerta you may now begin your conference. At this time, I would like to welcome everyone to the Orthofix Medical Third Quarter Earnings Conference Call. My name is Gavin and I will be your conference operator today. Mathew Blackman - Stifel, Nicolaus & Company Jon Serbousek - President, CEO & Director ( NASDAQ: OFIX) Q3 2022 Earnings Conference Call Novem8:30 AM ET
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |